A Lightweight, Bookbag-sized Realtime Pathogen Detection System, with Commercial Availability Slated for Summer 2018

A rendering of the FireflyDX-Portable from ExcitePCR: A Lightweight, Bookbag-sized Realtime Pathogen Detection System, with Commercial Availability Slated for Summer 2018

Designed for use in several multi-billion-dollar industries, ExcitePCR’s FireflyDX-Portable is a standalone, bookbag-sized bio-threat detection system that can be operated by virtually anyone and will deliver results in less than 30 minutes.”

ExcitePCR™ today announced the FireflyDX-Portable™, a rechargeable bookbag-sized realtime pathogen detection system that will enable first responders, medical professionals and food safety officials to accurately obtain on-site results anywhere in the world in less than 30 minutes … including sample preparation time.

The FireflyDX-Portable is designed for use in several multi-billion-dollar industries, markets where molecular diagnostics are critical to ensure rapid safety and treatment protocols. Unfortunately, today’s existing solutions for accurately identifying potential pathogens and bio-threats, especially at the Point-of-Care / Point-of-Need (POC / PON), can sometimes take as long as several hours to several days to provide results, dramatically delaying what is often life-saving treatment, while also increasing costs, both personal and financial. In addition, most state-of-the-art Polymerase Chain Reaction (PCR) solutions in use today for pathogen detection typically require a professionally trained operator working in a pristine laboratory setting and/or are heavy, bulky and tied to a personal computer to function properly.

By contrast, ExcitePCR’s FireflyDX-Portable is a standalone, bookbag-sized bio-threat detection system that can be operated by virtually anyone with minimal training yet still produces highly accurate results. In addition, the FireflyDX-Portable will deliver such results in under 30 minutes, including sample preparation (which generally takes the most time in pathogen detection).

“Recent market developments have inspired us to expand our development efforts onto a new path, one that will require little if any regulatory oversight initially, yet will allow us to solve the challenges faced by several markets,” said Lyle Probst, President, CEO and founder of…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *